LEXXW (Lexaria Bioscience) Long-Term Debt : $0.00 Mil (As of May. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lexaria Bioscience Long-Term Debt?

Lexaria Bioscience's Long-Term Debt for the quarter that ended in May. 2024 was $0.00 Mil.

Lexaria Bioscience Long-Term Debt Historical Data

The historical data trend for Lexaria Bioscience's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience Long-Term Debt Chart

Lexaria Bioscience Annual Data

Trend

Oct13

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Long-Term Debt

Get a 7-Day Free Trial

0.03

Lexaria Bioscience Quarterly Data
	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Lexaria Bioscience (NAS:LEXXW) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Lexaria Bioscience Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexaria Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXXW) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

LEXX:USA

Address

740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7

Website

https://www.lexariabioscience.com

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.